Trial Profile
An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Romidepsin (Primary) ; Dexamethasone
- Indications Hodgkin's disease; Multiple myeloma; T-cell lymphoma
- Focus Therapeutic Use
- Acronyms RID
- 29 Sep 2016 Status changed from recruiting to discontinued.
- 10 Jan 2013 New trial record